SCHEMBL30171303

CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)NCCCCCN

nearest known ligand 0.73

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	OPRD1	P41143	8/20	0.73

▸	NTSR1	P30989	3/20	0.64

▸	OPRM1	P35372	1/20	0.64

▸	OPRK1	P41145	1/20	0.64

▸	NMUR2	Q9GZQ4	2/20	0.62

▸	NMUR1	Q9HB89	2/20	0.62

▸	NTSR2	O95665	1/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Analog Of Dynorphin A SCHEMBL27861937	0.96	OPRD1 (0.75)	OPRD1NTSR1OPRM1OPRK1NMUR2
SCHEMBL11191224	0.96	OPRD1 (0.75)	OPRD1NTSR1OPRM1OPRK1NMUR2
SCHEMBL1421906	0.90	OPRD1 (0.69)	OPRD1NTSR1OPRM1OPRK1NTSR2
SCHEMBL1421931	0.90	OPRD1 (0.69)	OPRD1NTSR1OPRM1OPRK1NTSR2
SCHEMBL1421938	0.90	OPRD1 (0.69)	OPRD1NTSR1OPRM1OPRK1NTSR2
SCHEMBL1421888	0.90	OPRD1 (0.69)	OPRD1NTSR1OPRM1OPRK1NTSR2
SCHEMBL30416476	0.90	OPRD1 (0.69)	OPRD1OPRM1OPRK1NMUR2NMUR1
SCHEMBL30439395	0.90	OPRD1 (0.67)	OPRD1
SCHEMBL16573670	0.89	OPRD1 (0.64)	OPRD1NTSR1OPRM1OPRK1NMUR2
SCHEMBL30775521	0.89	NTSR1 (0.68)	OPRD1NTSR1OPRM1OPRK1NTSR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20240374689-A1	HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME	LONGEVITY BIOTECH, INC.	2024-11-14	—	—	US	disclosed
EP-4114941-A2	IMPROVED METHODS AND COMPOSITIONS FOR MODULATING A GENOME	Flagship Pioneering Innovations VI, LLC (US)	2023-01-11	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20240374689-A1	HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME	SCTR, GIPR, APLNR	OPRD1 501/4885NTSR1 18/4885OPRM1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.